We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 50

Snapshot of Sunshine rules in EU countries for the pharmaceutical industry part 1 - June 2014

  • McDermott Will & Emery
  • -
  • European Union, United Kingdom
  • -
  • June 12 2014

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. In 2013

Repackaging and parallel import of pharmaceutical products

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • May 22 2007

On 27 April 2007, the European Court of Justice (the “ECJ”) handed down yet another decision in the case of Boehringer Ingelheim & others v Swingward Ltd and Dowelhurst Ltd, Case C-34804 (“Boehringer II”

Controlling and processing data in EU clinical trials

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • November 22 2010

The legal regime for the conduct of clinical trials of medicinal products for human use in the European Union is set out in Directive 200120EC (the Clinical Trials Directive

Focus on regulatory law - June 2014

  • McDermott Will & Emery
  • -
  • European Union, France
  • -
  • June 3 2014

If an appeal is lodged against an AMF decision to levy a financial penalty, the appeal judge has to verify that the penalty is proportionate in

European Commission fines pharmaceutical companies for Citalopram pay-for-delay agreements

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • June 30 2013

On 19 June 2013, the European Commission announced a fine of 93.8 million for H. Lundbeck AS (Lundbeck) and a further 52.2 million of fines levied

SPCs: is a simplistic system becoming too complicated?

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • November 22 2010

Obtaining and enforcing Supplementary Protection Certificates (SPCs) for medicinal products in the European Union is a fertile ground for challenge and the law is still unclear in a number of key areas

Why life science patents are a breed apart

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • April 10 2007

Patents are creatures of statute. Once an applicant has disclosed an invention, and subject to the application meeting certain statutory standards as to form and content, the European Patent Office grants a 20-year “monopoly”

What did you say? $31 million awarded for infringement of hearing aid patent

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • November 29 2012

In a case involving the alleged infringement of two patents related to hearing aids, one of which was found under judgment as a matter of law (JMOL) to not be infringed

Mergers: Commission approves Nestlé’s acquisition of Novartis' Medical Nutrition business

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • July 6 2007

The European Commission has cleared the merger of Nestlé S.A. and Novartis' Medical Nutrition business (NMN) following a first phase investigation

Divergences in industrial applicability between the United Kingdom and the European Patent Office

  • McDermott Will & Emery
  • -
  • European Union, United Kingdom
  • -
  • April 30 2010

Rejecting an appeal by Human Genome Sciences Inc (HGS), the Court of Appeal of England and Wales in Eli Lilly and Co v Human Genome Sciences Inc 2010 EWCA Civ 33 upheld the finding that HGS' patent (as amended) was invalid for lack of industrial applicability